All patients are required to be pre-registered to A in order to submit post-radiation therapy (RT) bone marrow aspirate specimens to Roswell Park for MRD detection by flow cytometry; this submission is required prior to registration to confirm eligibility
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Relapsed or refractory B-cell or T-cell ALL after multi-agent chemotherapy (>= % marrow lymphoblasts, assessed by morphology and flow cytometry; flow cytometry will be used to confirm immunophenotype and percentage of blasts will be assessed by morphology)
ELIGIBILITY CRITERIA - PHASE II (ARM D): Relapsed or refractory B-cell or T-cell ALL after multi-agent chemotherapy (>= % marrow lymphoblasts, assessed by morphology and flow cytometry; flow cytometry will be used to confirm immunophenotype and percentage of blasts will be assessed by morphology)
Participants with > % involvement of bone marrow by malignant cells (either by manual count or flow cytometry) prior to stem cell collection
Previously untreated Ph negative precursor B-cell or T-cell ALL confirmed by conventional flow cytometry or immunohistochemical stain; patients who have untreated B-cell or T-cell ALL confirmed by conventional flow cytometry or immunohistochemical stain, but Ph status is unknown, may also enroll
Patients must have measurable disease requiring cytoreduction, defined as a bone marrow myeloblast count >= % and < % on morphologic examination or by flow cytometry in cases in which adequate morphologic examination is not possible
Available autologous transduced peripheral blood T-cells with >= % expression of CAR-Kappa determined by flow-cytometry
CD expression is required at any time since diagnosis; if patient has received anti-CD targeted therapy (i.e. blinatumomab), then CD expression must be subsequently demonstrated. CD expression must be detected on greater than % of the malignant cells by immunohistochemistry or >= % by flow cytometry; the choice of whether to use flow\r\ncytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject; in general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples
INCLUSION - PROCUREMENT: CD-positive tumor (result can be pending at this time); > % CD + blasts by flow cytometry or immunohistochemistry (tissue) assessed by a Clinical Laboratory Improvement Amendments (CLIA) certified flow cytometry/pathology laboratory
INCLUSION - TREATMENT: CD-positive tumor (> %) CD+ blasts by flow cytometry or immunohistochemistry (tissue) assessed in a CLIA certified flow cytometry/pathology laboratory
INCLUSION - TREATMENT: Available autologous activated peripheral blood T cell products with ? % expression of CD.CAR. zeta and < .% gene-modified malignant T blasts by flow cytometry
TREATMENT INCLUSION: Available autologous T cells with ? % expression of CDCAR determined by flow-cytometry
Biopsy-confirmed CD+ expression of the underlying malignancy by immunohistochemical staining or flow cytometry between the most recent dose of an anti-CD monoclonal antibody (mAb) and study enrollment
Patients with any history of relapsed/refractory disease, or who have progressed at any time since beginning induction therapy are not eligible; patients who have evidence of residual disease by FISH, cytogenetics, SNP array, or flow cytometry without any measurable nodal disease or morphologic evidence of disease in the bone marrow or peripheral blood are eligible
Patients will be eligible to receive donor-derived multiTAA-specific T cells following any type of allogeneic HSCT as\r\n* Adjuvant therapy for AML/MDS (Group A); or\r\n* Treatment for refractory/relapsed or minimal residual AML/MDS disease (Group B)\r\n** Residual disease at the time of transplant or post transplant relapse is defined as polymerase chain reaction (PCR) positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy, in the peripheral blood, or any other extramedullary sites\r\n* Minimal residual disease (MRD) will be defined as detection in blood, bone marrow, or other tissues any of the following:\r\n** Any leukemia specific marker such as t(;); inv ; t (;), t(;) or t(;) documented in the patients leukemia cells pre-transplant on a post-transplant evaluation\r\n** Expression of a leukemia associated antigen known to be a marker for residual disease like WT\r\n** A leukemia-specific phenotype (e.g. expression of markers including CD and/or CD and/or CD and/or human leukocyte antigenantigen D related positive [HLA-DR+]) post-transplant at a level of ? .%\r\n** Mixed donor chimerism (> %)
CD expression must be detected on greater than % of the malignant cells by immunohistochemistry or greater than % by flow cytometry; the choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patent; in general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples
Prior CAR therapy within  days prior to apheresis or prior CAR therapy at any time with evidence for persistence of CAR T cells in blood samples (circulating levels of genetically modified cells of >= % by flow cytometry)
Available allogeneic activated peripheral blood T cell products with ? % expression of CD.CAR-CDzeta determined by flow cytometry (cell dose is based on total cell numbers and not individual anti-leukemic cell numbers)
Patients multiple myeloma cells are positive for CD or CD expression by flow cytometry or immunohistochemistry (in any proportion)
CD expression must be detected on greater than % of the malignant cells by immunohistochemistry or greater than % by flow cytometry; the choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patient; in general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples; CD+ B cell malignancy is required and CD expression levels will be documented when available, but a specific level of expression is not an eligibility requirement; it may be documented as positive or negative
Prior CAR therapy within  days prior to apheresis or prior CAR therapy at any time with evidence for persistence of CAR T cells in blood samples (circulating levels of genetically modified cells of ? % in peripheral blood by flow cytometry)
The patients lymphoma must be CD positive, either by immunohistochemistry or flow cytometry analysis on the last biopsy available.
Evidence of CD expression by immunohistochemistry or flow cytometry on the tumor specimen obtained with the biopsy performed with screening
CD expression is required at any time since diagnosis; if patient has received anti-CD targeted therapy (i.e. blinatumomab or CD-CAR T cells), then CD expression must be subsequently demonstrated; CD expression must be detected on greater than % of the malignant cells by immunohistochemistry or >= % by flow cytometry; the choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject; in general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples
AML Blast cell expressing CD by flow cytometry performed as per standard practice
After CAR T cell infusion on PLAT-, the ratio of the % CAR T cells in peripheral blood on day  (as measured by flow cytometry) compared to the % CAR T cells in peripheral blood on day  is >= .\r\n* Patients meeting above criteria may enroll on Cohort B, but must demonstrate evidence of ongoing B cell aplasia (BCA) in the bone marrow within  days prior to planned T-APC test dose, in order to remain on Cohort B; BCA in the bone marrow is defined as < % CD+ cells, as measured by flow cytometry; patients not demonstrating ongoing BCA may be considered for enrollment on Cohort C of this study
Following CAR T cell infusion on PLAT-, patient initially achieved BCA and has now lost BCA in the bone marrow or peripheral blood, before  months; BCA is defined as < % CD+ cells by lymphocyte subset testing, as measured by flow cytometry\r\n* If patient has disease relapse in this setting, disease must remain CD+
Evidence of CD expression via flow cytometry (peripheral blood or bone marrow) or immunohistochemistry (bone marrow biopsy) from a sample obtained from the current relapse
Patients must have bone marrow and peripheral blood studies available for confirmation of diagnosis of AML; CD positivity must be confirmed by either flow cytometry or immunohistochemistry; cytogenetics, flow cytometry, and molecular studies (such as FMS-like tyrosine kinase- [Flt-] status) will be obtained as per standard practice.
Diagnosis of B- or T-ALL or LLy by immunophenotyping:\r\n* LLy participants must have < % tumor cells in bone marrow and peripheral blood by morphology and flow cytometry; if any of these show >= % blasts, patient will be considered to have leukemia
CELL PROCUREMENT: CD positivity of lymphoblasts confirmed by flow cytometry or immunohistochemistry (IHC) per institutional standards
Phase I portion of the study: Histologically or flow cytometry confirmed diagnosis of B-CLL/SLL according to National Cancer Institute (NCI)-Working Group (WG)  guidelines
Phase II portion of the study - histologically or flow cytometry confirmed diagnosis of BCLL/SLL according to NCI-WG  guidelines; patients who lack CD expression on their leukemia cells should be examined for (and found NOT to have) either t(;) or cyclin D overexpression, to rule out mantle cell lymphoma
Leukemia or myelodysplastic syndrome (MDS) in aplasia; these patients may be taken to transplant if after induction therapy they remain with aplastic bone marrow and no morphological or flow-cytometry evidence of disease >=  days post-therapy; these high risk patients will be analyzed separately
Bone marrow and peripheral blood studies must be available for confirmation of diagnosis; cytogenetics, flow cytometry, and molecular studies (such as JAK-, MPL and CALR mutational status) will be obtained as per standard practice
Response to therapy and completion of at least one cycle of consolidation therapy, and with disease status meeting one of the following criterion at the time of post-induction disease restaging:\r\n* Minimal residual disease, as defined by detectable disease by flow cytometry but with marrow that is at least % cellular with < % blasts on morphologic review\r\n* Complete remission with incomplete blood count recovery (CRi)/complete remission with incomplete platelet recovery (CRp), as defined by absence of detectable disease by flow cytometry, and marrow that is at least % cellular with < % blasts on morphologic review, but with neutrophil count < /ul (CRi) and/or platelet count < ,/ul (CRp); in pediatric patients, a platelet threshold of < ,/ ul will be used, as per consensus pediatric response criteria
Response to therapy and completion of at least one cycle of consolidation therapy, and with disease status meeting one of the following criterion\r\n* Minimal residual disease, as defined by detectable disease by flow cytometry but with marrow that is at least % cellular with < % blasts on morphologic review\r\n* CRi/CRp, as defined by absence of detectable disease by flow cytometry, and marrow that is at least % cellular with < % blasts on morphologic review, but with neutrophil count < /ul and/or platelet count <,/ul. As previously stated, a platelet threshold of < ,/ul will be used to define CRp in pediatric patients, as per consensus pediatric response criteria\r\n* Elevated expression above of WT in bone marrow or peripheral blood; (increased expression of WT will be determined if the number of copies of WT divided by the number of copies of ABL x ^ is >  for bone marrow, or >  for peripheral blood)
Leukemia or MDS in aplasia; these patients may be taken to transplant if after induction therapy they remain with aplastic bone marrow and no morphological or flow-cytometry evidence of disease >=  days post-therapy; these high risk patients will be analyzed separately
Evidence of ROR expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen
PRIOR TO LYMPHODEPLETION: Available autologous T cells with ? % expression of CDCAR determined by flow cytometry required prior to treatment with ATLCAR.CD cells
PRIOR TO INFUSION OF ATLCAR.CD CELLS: Available autologous T cells with ? % expression of CDCAR determined by flow-cytometry required prior to treatment with ATLCAR.CD cells
Abnormal T cells must be CD+ as assessed by flow cytometry or immunohistochemistry
Cohort : Persistence or reappearance of minimal residual disease by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation
Please note that tumor samples for patients with MF or SS can be CD negative and do not have to be CD positive on either flow cytometry or immunohistochemistry for patients to be eligible
Confirmed history of CD positivity by flow cytometry for malignant cells
AT THE TIME OF INFUSION: Available autologous transduced T lymphocytes with ? % expression of HER CAR determined by flow cytometry and killing of HER-positive targets ? % in cytotoxicity assay
Documented genetic lesion(s) known to confer susceptibility to inhibition by either ruxolitinib or dasatinib or cytokine receptor-like factor  (CRLF) positivity by flow cytometry (for the ruxolitinib cohort)
A measurable residual disease at the time of screening defined as at least MRD-positive disease:\r\n* A method of evaluation of MRD is multi-parameter flow cytometry (MFC) performed at the University of Chicago\r\n* Patients who have negative MRD by multi-parameter flow cytometry (MFC) but have residual original monoclonal protein by serum or urine immunofixation may be eligible if they are found to have MRD-positive disease by next generation sequencing (NGS)
Evidence of MRD at the time of screening for this study by multi-color flow cytometry (bone marrow procedure at screening required)
Histologic verification of B-cell lineage leukemia or B cell non-Hodgkin lymphoma and evidence of relapse/refractory disease with the presence of CD and/or CD by flow cytometry or immunohistochemistry of bone marrow aspirate, peripheral blood or node/tumor biopsy
Evidence of marrow disease by flow and morphology after upfront or salvage cytoreductive therapy and before stem cell mobilization
Patients with T cell acute lymphoblastic leukemia (ALL) must be in complete remission and minimal residual disease (MRD) negative (-) by flow cytometry and molecular studies
FOR BOTH STUDY ARMS: Research participants must have bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML or BPDCN; CD positivity must be confirmed by either flow cytometry or immunohistochemistry within  days of study entry; cytogenetics, flow cytometry, and molecular studies (such as FMS-like tyrosine kinase- [FLT-] status) will be obtained as per standard practice; however, for research participants who are at a high risk of recurrence, they must have historical bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML or BPDCN; CD positivity must be confirmed by either flow cytometry or immunohistochemistry prior to start of lymphodepletion
Available autologous or syngeneic activated peripheral blood T cell products (CDzeta and CD/CDzeta) with >= % expression of CD.CAR determined by flow cytometry
HLA-A positive based on flow cytometry
History of CD+ malignancy with evidence of relapse or persistent minimal residual disease (MRD) following autologous or allogeneic hematopoietic stem cell transplantation (cohort )\r\n* Relapse on this protocol is detection of CD+ malignancies in bone marrow (>= %) or extramedullary lesion by morphology, cytogenetics, molecular, radiographic, and/or flow cytometry\r\n* Persistent minimal residual disease after transplantation must be demonstrated by morphology, karyotype, fluorescent in situ hybridization (FISH), flow cytometry, or reverse transcriptase (RT)-polymerase chain reaction (PCR)
Measurable disease for dose expansion and lead in phases only; measurable disease defined by:\r\n* Revised International Working Group (Cheson, ) classification for systemic lymphoma or \r\n* Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood\r\n* Or bone marrow modified severity weighted assessment tool (mSWAT) >  or Sezary count >=  cells/uL
Available autologous transduced EBV-specific cytotoxic T lymphocytes with >= % expression of CDCAR determined by flow-cytometry
HLA-A positive based on flow cytometry
CD expression must be detected on the majority of the malignant cells by immunohistochemistry or by flow cytometry in the Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH; definition of which cells are malignant must be determined for each patient by the Laboratory of Pathology using techniques to demonstrate monoclonality such as kappa/lambda restriction (other techniques can be used to determine monoclonality at the discretion of the Laboratory of Pathology); the choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patient. Immunohistochemistry will be used for lymph node biopsies and bone marrow biopsies; flow cytometry will be used for peripheral blood, fine needle aspirate, and bone marrow aspirate samples
AML or MDS relapse following allo-HSCT (morphological relapse, or MRD positive by flow cytometry, cytogenetics, molecular mutations)
Confirmed history of CD-positivity by flow cytometry for malignant cells.
Expansion cohort - histologically or flow cytometry confirmed diagnosis of B-CLL/SLL according to NCI-WG  guidelines; patients who lack CD expression on their leukemia cells should be examined for (and found NOT to have) either t(;) or cyclin D overexpression, to rule out mantle cell lymphoma
Detectable clonal bone marrow plasma cells by multicolor flow cytometry and less than % clonal plasma cells in a bone marrow biopsy by immunohistochemistry, morphology, or flow cytometry
Pre-registration: Diagnostic bone marrow and peripheral blood specimens must be submitted for eligibility testing by multiparameter flow cytometry; testing will be performed by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) Leukemia Translational Studies Laboratory and reported to the institution
Recipient leukocyte infusion (RLI) might involve the infusion of circulating tumor cells to the patients; to minimize this risk, patients who have evidence of circulating tumor cells by light microscopy and flow cytometry will be excluded
Patients will NOT receive a second infusion of GD- CAR T cells if >=  % of the circulating T cells are GD-CAR positive by flow cytometry
Bone marrow and peripheral blood studies must be available for confirmation of diagnosis; cytogenetics, flow cytometry, and molecular studies (such as Flt- status) will be obtained as per standard practice
CD+ bone marrow or lymph node by immunohistochemistry or flow cytometry\n                  obtained within  days prior to registration
CD expression must be detected on greater than % of the malignant cells by immunohistochemistry or greater than % by flow cytometry in a Clinical Laboratory Improvement Amendments (CLIA) approved test in the Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH) or from the referring institution or reference laboratory; the choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patient; in general immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples
Patients with evidence of myelodysplasia, leukemia by morphology, immunostains flow cytometry or abnormal cytogenetics on a bone- marrow aspirate or biopsy; the diagnosis of myelodysplasia will be made by an independent investigator of the Laboratory of Pathology, National Cancer Institute (NCI) taking into consideration the totality of the clinical, pathological, flow cytometric and cytogenetic and present in a particular individuals evaluation
Available autologous transduced EBV-specific cytotoxic T lymphocytes with >= % expression of HER CAR determined by flow-cytometry and killing of HER-positive targets >= % in cytotoxicity assay
Presence of circulating lymphoma cells by morphology or flow cytometry (> .%) at or near the time of peripheral blood stem cell (PBSC) collection if unpurged/unselected PBSC are to be used (patients with cryopreserved stem cells which are negative [=< .% involved] by flow cytometry will also be considered eligible)
Available autologous transduced peripheral blood T-cells with >= % expression of CDCAR determined by flow-cytometry
For relapsed patients, CD tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry within  months of study entry
For relapsed patients, documentation of CD tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry within  months of study entry.
PNH diagnosis confirmed by documented by high-sensitivity flow cytometry
PNH diagnosis confirmed by documented by high-sensitivity flow cytometry.
Neoplastic mast cells must express CD by immunohistochemistry or flow cytometry
Bone marrow and peripheral blood studies must be available for confirmation of diagnosis; cytogenetics, flow cytometry, and molecular studies (such as Fms-like tyrosine kinase  [FLT-] status) will be obtained as per standard practice
Available autologous T cells with >= % expression of CDCAR determined by flow-cytometry
Measurable disease defined by: \r\n* Lugano classification for systemic lymphoma or\r\n* Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood or bone marrow or \r\n* Modified severity-weighted assessment tool (mSWAT) >  or Sezary count >=  cells/uL for CTCL
Have documented CD expression by leukemic cells via flow cytometry (a \blast gate\ on CD vs. side scatter analysis consistent with AML)
Diagnosis of PNH by flow cytometry
Additionally, patients who were previously MRD negative for >=  months after induction therapy with/without consolidative HDT/ASCT and have turned MRD positive (by flow cytometry) within the last  months and do not have any evidence of progressive disease are eligible.
Patient must have > % disease burden measured by cytomorphology, flow cytometry, or cytogenetics
Individuals whose lymphoblasts have surface immunoglobulin by flow cytometry and/or known t(;), t(;), or t(;); absence of surface immunoglobulin by flow cytometry at time of initial diagnosis or relapse is sufficient to rule out mature B-cell leukemia; karyotype or fluorescent in situ hybridization (FISH) results documenting absence of t(;), t(;), or t(;) are not necessary prior to enrollment if absence of surface of immunoglobulin is documented by flow cytometry
At least  of the following high-risk features for previously untreated patients:\r\n* Rai stage II disease\r\n* Rai stage -I with disease-related fatigue\r\n* Serum beta  microglobulin (betaM) >=  mg/L\r\n* Absolute lymphocyte count >= ,/uL\r\n* Unmutated immunoglobulin heavy variable cluster (IGHV) gene or IGHV-\r\n* Zeta-chain-associated protein kinase kDa (ZAP) positive (>= % by flow cytometry or positive by immunohistochemistry)\r\n* CD positive (>= % by flow cytometry); OR\r\n* Deletion q or p by fluorescent in situ hybridization (FISH)
Tissue diagnosis of lymphoplasmacytic lymphoma with surface immunoglobulin G (IgG), immunoglobulin A (IgA) or immunoglobulin M (IgM) phenotype with a monoclonal heavy and light chain as determined by flow cytometry; all primary diagnostic lymph node and/or bone marrow biopsies will be reviewed at the University of Texas M.D. Anderson Cancer Center (UTMDACC)
Patients must have a diagnosis of B-ALL by flow cytometry, bone marrow histology, and/or cytogenetics
Patients must have CD+ acute lymphoblastic leukemia (ALL) as confirmed by flow cytometry and/or immunohistochemistry
Diagnosis of CLL by immunophenotyping and flow cytometry analysis of blood or bone marrow.
Confirmed B-cell CLL/SLL with a characteristic immunophenotype by flow cytometry, and symptomatic disease requiring treatment
Confirmation of diagnosis of B cell malignancy and positivity for CD confirmed by the Laboratory of Pathology of the National Cancer Institute (NCI); the choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patient; immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood, fine needle aspirates and bone marrow samples
With minimal residual disease (MRD) or relapse post-HSCT (for the phase I dose escalation) as evidenced by polymerase chain reaction (PCR) positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy or in the peripheral blood
Available allogeneic CDCAR transduced tri-virus-specific cytotoxic T lymphocytes with >=% expression of CDCAR determined by flow cytometry and greater than % killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of :
Evidence of bone marrow MRD defined as ? .% by flow cytometry performed in the study central lab
Patients with leukemic form of PTCL who will not have a measurable lesion in two dimensions by CT scan, relapsed or refractory disease must be detected by immunohistochemistry or flow cytometry and molecular clonality studies in bone marrow or peripheral blood
Greater than % aberrant intraepithelial lymphocytes (IEL) as assessed by flow cytometry
Histological diagnosis of Diffuse Large B Cell Lymphoma (de novo or transformed) expressing CD by immunohistochemistry or flow cytometry analysis (>% positivity), based on recent (less than  months) or new biopsy.
Presence of hepatopetal flow
Bone marrow and peripheral blood studies must be available for confirmation of diagnosis; cytogenetics, flow cytometry, and molecular studies (such as JAK-, myeloproliferative leukemia [MPL] and calreticulin [CALR] mutational status) will be obtained as per standard practice
Available autologous T cells with >= % expression of CDCAR determined by flow-cytometry required prior to treatment with ATLCAR.CD cells
The evidence of CD+ expression on leukemia cells must be confirmed by pathology review of the bone marrow and/or peripheral blood specimens (flow cytometry and/or immunohistochemistry) collected at the time of current relapse and prior to the initiation of therapy